Nothing Special   »   [go: up one dir, main page]

Ariga et al., 2005 - Google Patents

Antiglycolipid antibodies in Guillain‐Barre syndrome and related diseases: review of clinical features and antibody specificities

Ariga et al., 2005

Document ID
5838976708411104349
Author
Ariga T
Yu R
Publication year
Publication venue
Journal of neuroscience research

External Links

Snippet

Guillain‐Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy that usually develops following a respiratory or intestinal infection. Although the pathogenic mechanisms of GBS have not been fully established, both humoral and cell‐mediated …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Similar Documents

Publication Publication Date Title
Ariga et al. Antiglycolipid antibodies in Guillain‐Barre syndrome and related diseases: review of clinical features and antibody specificities
Yuki et al. Animal model of axonal Guillain‐Barré syndrome induced by sensitization with GM1 ganglioside
Willison et al. Peripheral neuropathies and anti‐glycolipid antibodies
Lunn et al. High‐affinity anti‐ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization
Lo Clinical and immunological spectrum of the Miller Fisher syndrome
Yu et al. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases
Plomp et al. Pathophysiological actions of neuropathy‐related anti‐ganglioside antibodies at the neuromuscular junction
Willison The immunobiology of Guillain‐Barre syndromes
Goodfellow et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy
Susuki et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies
Willison et al. The immunopathogenesis of Miller Fisher syndrome
Lopez et al. Passive transfer of IgG anti-GM1 antibodies impairs peripheral nerve repair
US9388235B2 (en) Methods and compositions for the treatment of antibody mediated neuropathies
Sheikh et al. An anti‐ganglioside antibody‐secreting hybridoma induces neuropathy in mice
Usuki et al. Novel anti‐idiotype antibody therapy for lipooligosaccharide‐induced experimental autoimmune neuritis: Use relevant to Guillain‐Barré syndrome
Komagamine et al. Ganglioside mimicry as a cause of Guillain-Barre syndrome
Yu et al. The Role of Glycosphinglipids in Neurological Disorders: Mechanisms of Immune Action a
Nores et al. Anti-GM1 antibodies as a model of the immune response to self-glycans
Rojas‐García et al. Clinical and serological features of acute sensory ataxic neuropathy with antiganglioside antibodies
Ariga et al. Recent studies on the roles of antiglycosphingolipids in the pathogenesis of neurological disorders
Fredman The Role of Antiglycolipid Antibodies in Neurological Disorders a
Yuki et al. Guillain‐Barré Syndrome and Fisher's Syndrome Following Campylobacter jejuni Infection a
Yuki Current cases in which epitope mimicry is considered a component cause of autoimmune disease: Guillain-Barré syndrome
Willison Gangliosides as targets for autoimmune injury to the nervous system
Usuki et al. Development of a novel therapy for Lipo‐oligosaccharide‐induced experimental neuritis: use of peptide glycomimics